Global Bleeding Disorder Testing Market Size study & Forecast, by Product Type (Reagents & Consumables, Instruments) by Indication (Hemophilia A, Hemophilia B, Von Willebrand Disease, Idiopathic Thrombocytopenic Purpura, Others), by End-user (Hospitals &

Global Bleeding Disorder Testing Market Size study & Forecast, by Product Type (Reagents & Consumables, Instruments) by Indication (Hemophilia A, Hemophilia B, Von Willebrand Disease, Idiopathic Thrombocytopenic Purpura, Others), by End-user (Hospitals & Clinics, Diagnostic Centers, Others) and Regional Analysis, 2022-2029

Global Bleeding Disorder Testing Market is valued at approximately USD 82.6 million in 2021 and is anticipated to grow with a healthy growth rate of more than 7.8% over the forecast period 2022-2029. Bleeding disorder is a condition that affects when the blood clotting process and resulting in excessive bleeding. This disorder is caused by the low levels of clotting protein that is present in blood. Bleeding disorder testing is a screening test that is performed to detect bleeding disorders in people who have not shown any symptoms of disease. Factors such as favorable reimbursement scenarios, rising integration of artificial intelligence and nanomaterials in testing and diagnosis, coupled with the growing healthcare expenditure are the chief driving factors for the market demand around the world.

The increasing prevalence and diagnosis of bleeding disorder among general population is acting as a catalyzing factor for the growth of the market. According to The Centers for Disease Control and Prevention, it was estimated that Hemophilia A affects 1 in 5,000 male births and nearly 400 babies are born with hemophilia A each year. Likewise, as per the World Federation of Hemophilia's 2020 annual global survey, there were around 393,658 individuals worldwide recorded who suffer from bleeding disorders, which is an increase from about 287,066 in 2015. This surge occurs because of a rise in the disorder's prevalence among diagnoses in the general population, thus, in turn, accelerates the market growth across the globe. Moreover, the rising introduction of new products, as well as the growing R&D investment by the key market players are presenting various lucrative opportunities over the forecasting years. However, the low adherence to guidelines and high cost of hemophilia drugs are hampering the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Bleeding Disorder Testing Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. Europe dominated the market in terms of revenue, owing to the rising adherence to the guidelines for diagnosis of these disorders and the rising number of regulatory approvals. Whereas, the Asia Pacific is also expected to grow with the highest CAGR during the forecast period, owing to factors such as development of healthcare infrastructure in emerging countries, rising prevalence of bleeding disorder, and rising number of patient population in the market space.

Major market players included in this report are:
F. Hoffmann-La Roche Ltd.
Siemens Healthcare GmbH
HORIBA Ltd.
Sysmex Corporation
Abbott
Thermo Fisher Scientific Inc.
Biomerica, Inc.
Becton, Dickinson, and Company
Quest Diagnostics
Trinity Biotech Plc

Recent Developments in the Market:
 In July 2022, HORIBA, Ltd. announced the launch of the company’s new product Yumizen H500 and H550 hematology which offers better performance, new features, and increased benefits.
 In February 2022, Sysmex Corporation unveiled the establishment of Sysmex LLC- the company’s new subsidiary in Saudi Arabia. The aim of this initiative is to boost the sales and services structure in Saudi Arabia. The new subsidiary is emphasizing on strengthening its hemostasis, hematology, and urinalysis markets.


Global Bleeding Disorder Testing Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Product Type, Indication, End-user, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.
The detailed segments and sub-segment of the market are explained below:

By Product Type:
Reagents & Consumables
Instruments
By Indication:
Hemophilia A
Hemophilia B
Von Willebrand Disease
Idiopathic Thrombocytopenic Purpura
Others
By End-user:
Hospitals & Clinics
Diagnostic Centers
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned

F. Hoffmann-La Roche Ltd.
Siemens Healthcare GmbH
HORIBA Ltd.
Sysmex Corporation
Abbott
Thermo Fisher Scientific Inc.
Biomerica, Inc.
Becton, Dickinson, and Company
Quest Diagnostics
Trinity Biotech Plc

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.